Walter Linz

Walter Linz

Auto-generated profile, based on publicly available information

Walter Linz

Department of Pathology and Laboratory Medicine Baylor Scott and White Central Texas Temple Texas USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2020 in Journal of Clinical Apheresis
Verified
Journal Article
Closed access
PDF file
WLWalter Linz
Walter Linz
CAChester Andrzejewski
Chester Andrzejewski
DWDing Wen Wu
Ding Wen Wu
YLYanhua Li
Yanhua Li
TRTimothy Roberts
Timothy Roberts
JHJan Hofmann
Jan Hofmann

28 March 2019 in Baylor University Medical Center Proceedings
Verified
Journal Article
Closed access
DJDeborah Jebakumar
Deborah Jebakumar
PBPatti Bryant
Patti Bryant
WLWalter Linz
Walter Linz
Cytomegalovirus (CMV) infection and CMV disease are significant contributors to increased morbidity, mortality, and cost for immunocompromised solid organ transplant recipients. Although the most significant risk for CMV transmission is the CMV serological status of the transplant donor and recipient, exposure to blood products is another potential risk factor. Before the era of leukocyte reduction, CMV seronegative products were issued to reduce the risk of CMV transmission, thus rendering the products CMV safe. This approach requires maintenance of two inventories of blood products and continuous donor testing. Leukocyte-reduced cellular transfusion products are also considered CMV safe and are essentially universally available. To minimize the risk of CMV infection in transplant recipients, strategies include use of seronegative blood products or prestorage leukocyte reduction. However, no recent randomized prospective controlled trial directly compares the two CMV safety approaches for transplant recipients. Hence, current policy relies on historic trials and more recent observational studies. As a consequence, though generally considered equivalent approaches, preferred practice varies between centers. This review provides guidance to inform an acceptable practice approach.


3 February 2021 in Journal of Clinical Apheresis
Verified
Journal Article
Closed access
PDF file
WLWalter Linz
Walter Linz
PAPriya Arunachalam
Priya Arunachalam
EGEvan George
Evan George
TYTimothy Yadegar
Timothy Yadegar
PRPaula Robinson
Paula Robinson

21 May 2003 in Transfusion
Verified
Journal Article
Closed access
PDF file
WLWalter J. Linz
Walter J. Linz
SMSheila Muenster
Sheila Muenster
JWJennifer Watkins
Jennifer Watkins
SMS. Breanndan Moore
S. Breanndan Moore

8 September 2026 in Transfusion
Verified
Journal Article
Closed access
PDF file
SLSamantha Little
Samantha Little
KMKristen Mathieu
Kristen Mathieu
RBRyan Benavente
Ryan Benavente
TFTristan Furnary
Tristan Furnary
JKJennifer Kapral
Jennifer Kapral
NRNakul Raykar
Nakul Raykar